(2017 - 2019)
(1990 - 1999)
2017
Cambridge Innovation Capital backs world-leading life sciences and deep tech companies with a connection to Cambridge UK, Europe’s leading innovation ecosystem. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. Since our inception in 2013, we have raised over £500 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics.
2021
2021
Epitopea is developing accessible "off-the-shelf" cancer immunotherapies that will deliver durable benefits. To achieve this, the company is exploiting a novel class of untapped tumour-specific antigens (TSAs), Cryptigen TSAs, designed to treat a broad patient population.
2019
2019
Start Codon identifies and recruits high potential life science and healthcare companies from across the UK and beyond, provides seed-funding, and leverages the world-class resources of the Cambridge ecosystem to reduce risk and prepare them for a successful Series A fundraise.
2018
2018
Congenica is a digital health company enabling genomic medicine with the world’s leading clinical decision support platform for the interpretation of complex genomic data.
2018 - 2023
2018 - 2023
STORM Therapeutics is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.
2017 - 2020
2017 - 2020
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA.
2014 - 2018
2014 - 2018
Proteorex is a biotechnology company developing small molecule therapeutics that target protein-protein interactions implicated in disease.
2010 - 2017
2010 - 2017
The Boston Consulting Group is a global management consulting firm and the world's leading advisor on business strategy. BCG partners with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. I focused on serving multinational clients in the Health Care sector, with extensive experience working in Canada, USA, UK, India, and Japan.
2008 - 2009
2008 - 2009
Oxford Capital is a UK-based venture capital firm that specializes in investing in UK headquartered, but globally focused, science and technology businesses. I was responsible for originating, evaluating, and monitoring investments in the health care and cleantech sectors.